|Assessment Status||Assessment process complete|
|Drug||Hydrocortisone modified-release hard capsules|
|Indication||For the treatment of congenital adrenal hyperplasia in adolescents aged 12 years and over and adults.|
|Rapid review commissioned||08/09/2021|
|Rapid review completed||04/11/2021|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that Efmody® not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.